

DAFTAR PUSTAKA

1. Babacan A, Şenol FF. Thrombocytosis in children. *Rev Assoc Med Bras*. 2023;69(6):16-19. doi:10.1590/1806-9282.20230020
2. Clarke C, Hamilton W, Price S, Bailey SER. Association of non-malignant diseases with thrombocytosis: A prospective cohort study in general practice. *Br J Gen Pract*. 2020;70(701):E852-E857. doi:10.3399/BJGP20X713501
3. Accurso V, Santoro M, Mancuso S, et al. The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. *Clin Med Insights Blood Disord*. 2020;13. doi:10.1177/2634853520978210
4. Barbui T, Thiele J, Ferrari A, Vannucchi AM, Tefferi A. The new WHO classification for essential thrombocythemia calls for revision of available evidences. *Blood Cancer J*. 2020;10(2):20-25. doi:10.1038/s41408-020-0290-9
5. Rokkam VR, Killeen RB KR. Secondary Thrombocytosis. *Natl Libr Med*. Published online 2024.
6. Kim MK, Lee KH, Hyun MS BS. An Audit of Inpatient Consultations to a Hematology Department over Two-Year Period. *Blood*. 2005;106(11):5571-5576.
7. Ashorobi D GP. Essential Thrombocytosis. *NCBI*. Published online 2023.
8. Shen CL, Hsieh TC, Wang TF, Huang WH, Chu SC, Wu YF. Designing a Scoring System for Differential Diagnosis From Reactive Thrombocytosis and Essential Thrombocytosis. *Front Med*. 2021;8(December):1-7. doi:10.3389/fmed.2021.736150
9. Almanaseer A, Chin-Yee B, Ho J, et al. An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis. *Adv Hematol*. 2024;2024(Cml):1-7. doi:10.1155/2024/3056216
10. Bellucci S MJ. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. *Thieme Med Publ*. Published online 2006. doi:10.1055/s-2006-942759
11. Selvaraju V, Jayaganesh J, Nikshayaa N. Platelet Indices in Differentiating Reactive Versus Clonal Thrombocytosis. *Saudi J Pathol Microbiol*. 2023;8(03):50-54. doi:10.36348/sjpm.2023.v08i03.002
12. Lotfy AERM, Ahmed AZES, Fahmy EM. Thrombocytosis in children: Clinical and hematological study in pediatric department, sohag university hospital. *Egypt J Hosp Med*. 2021;84(1):2435-2441. doi:10.21608/ejhm.2021.184663
13. Zulkafli Z, Janaveloo T, Wan Ab Rahman WS, Hassan MN, Abdullah WZ. Extreme thrombocytosis in a child: Laboratory approaches and diagnostic challenges. *Oman Med J*. 2019;34(4):336-340. doi:10.5001/omj.2019.65.
14. Firadayanti, Uma A, Al E. *Dasar-Dasar Hematologi*. Pertama. (Yunus R, Yuniarty T, eds.). EUREKA MEDIA AKSARA; 2024.
15. El Brihi J PS. Normal and Abnormal Complete Blood Count With Differential. *Natl Libr Med*. Published online 2024.
16. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. *Blood*. 2008;111(1):60-70. doi:10.1182/blood-2007-05-091850
17. Tafazzoli M, Keramati MR, Vakili R. Etiology of thrombocytosis and the use of platelet parameters to distinguish between clonal and reactive thrombocytosis. *UHOD*. 2006;16(2):71-76.

18. Venkat RK, Redd RA, Harris AC, Aryee MJ, Marneth AE, Kamaz B, Kim C, Wazir M, Weeks LD, Stahl M, DeAngelo DJ, Lindsley RC, Luskin MR, Hobbs GS, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. *Blood Adv.* 2024;8(23):6043-6050. doi:10.1182/bloodadvances.2024013777.
19. Hafeez A, Khattak D, Naeem S, Robert HM, Mohsin S, Mahmood A. Platelet Indices as a Tool for Differentiation between Clonal Thrombocytosis and Reactive Thrombocytosis. 2023;73:79-83. doi:10.51253/pafmj.v73iSUPPL-1.6350
20. Ozturk N, Baygutalp NK, Bakan E, Altas GF, Polat H, Dorman E. Changes in platelet parameters in leukocytosis. *Pan Afr Med J.* 2016;24:185. doi:10.11604/pamj.2016.24.185.7510
21. Tekin TO, Karis D, Ates Alkan F, Cetin G, Ercan AM. Evaluation of trace elements in essential thrombocytosis and reactive thrombocytosis. *J Trace Elem Med Biol.* 2022;73:127034. doi:<https://doi.org/10.1016/j.jtemb.2022.127034>
22. Chang SH. Platelet parameters and their role in myeloproliferative neoplasms, immune-mediated thrombocytopenia, and myelodysplastic syndrome. *Lab Med.* 2025;56(6):715-721. doi:10.1093/labmed/lmaf033